In conclusion, despite these limitations and based on the analysis of the main outcome mortality, this overview of systematic reviews supports the safety and efficacy of the clinical use of CP over standard therapy when administered at high titer and early during the course of COVID-19. The gene discussed is CP; the disease is COVID-19.